Lentiviral Vector (LV) Packaging

1. Overview   

Lentivirus belongs to the family Retroviridae and is named for its characteristically long incubation period following infection. In gene engineering, lentiviral vector systems are gene delivery tools developed on the basis of HIV-1 (Human Immunodeficiency Virus type 1) through multiple generations of safety engineering. Modern lentiviral vectors have had all pathogenicity-related genes removed, retaining only the cis-acting elements essential for viral replication, packaging, and transduction. The result is a safe, highly efficient platform for gene therapy and functional genomics research.

2. Vector Composition

Conventional lentiviral systems are predominantly based on the three-plasmid system. For applications demanding higher safety or higher packaging efficiency, the four-plasmid system is employed instead. Compared with the three-plasmid system, the four-plasmid system splits the packaging plasmid into two separate plasmids, which further reduces the risk of generating replication-competent lentiviruses (RCLs) through recombination. Meanwhile, it allows independent optimization of the expression level of each component, thereby improving viral packaging titer.

2.1 Three-Plasmid System

2.1.1   Transfer Vector

• 5′ Long Terminal Repeat (5′LTR)

• Ψ packaging signal sequence

• Gene expression cassette for the gene of interest (promoter – GOI – polyA signal)

• Central polypurine tract (cPPT) and WPRE enhancer element

• 3′ Self-inactivating Long Terminal Repeat (3′ΔLTR)

2.1.2 Packaging Plasmid

• gag gene: encodes viral structural proteins (MA, CA, NC, etc.)

• pol gene: encodes reverse transcriptase, integrase, and protease

2.1.3 Envelope Plasmid

• Typically uses a VSV-G (Vesicular Stomatitis Virus G protein) pseudotyped envelope

• Confers broad host range tropism to the viral particle

2.2 Four-Plasmid System

2.2.1 Transfer Vector

• Carries the gene of interest expression cassette (promoter – GOI – polyA signal)

• Contains cis-acting elements: 5′LTR, Ψ packaging signal, cPPT, WPRE, and 3′ΔLTR

2.2.2 gag/pol Packaging Plasmid

• Encodes gag (MA, CA, NC structural proteins) and pol (reverse transcriptase, integrase, protease) genes

• All accessory genes (env, vpr, vif, vpu, nef) have been deleted to maximize safety

2.2.3 Rev Helper Plasmid

• Encodes the Rev protein, which recognizes the Rev Response Element (RRE) on viral RNA and mediates nuclear export of unspliced gag/pol mRNA

• Separated from the gag/pol plasmid so that neither component alone can produce infectious particles without Rev, significantly enhancing biosafety

2.2.4 Envelope Plasmid

• Typically employs VSV-G pseudotyped envelope for broad host range; may be substituted with alternative envelope proteins for targeting specific cell types

• Completely independent from the other three plasmids; the envelope gene sequence shares no homology with the viral genome, fundamentally eliminating the possibility of recombination to yield wild-type virus

Fig1. Schematic of Three-Plasmid and Four-Plasmid Packaging Systems

2.3 Comparison of Three-Plasmid vs. Four-Plasmid Systems

• Biosafety: The four-plasmid system separates Rev from the gag/pol plasmid. No combination of any two plasmids is sufficient to generate a complete RCL, making it the preferred choice for GMP-grade clinical manufacturing.

• Titer: Independent expression of the Rev plasmid allows separate optimization of its promoter strength and copy number, unconstrained by gag/pol co-expression. Packaging titers are typically 2–5 fold higher than the three-plasmid system.

• Flexibility: Each plasmid can be independently substituted or optimized—for example, swapping envelope proteins for cell-type targeting or exchanging the transfer vector for a different gene of interest—without rebuilding the entire system.

• Use Cases: The three-plasmid system is simpler and well-suited for routine research. The four-plasmid system is preferred for high-titer production, preclinical/clinical-grade manufacturing, and projects with zero RCL tolerance (e.g., CAR-T cell therapy, hematopoietic stem cell gene therapy).

3. Core Technology & Advantages

3.1 Transduction of Both Dividing and Non-Dividing Cells

The most significant advantage of lentiviral vectors is their ability to transduce cells at any stage of the cell cycle, including terminally differentiated, post-mitotic cells. This property arises from the active nuclear import capability of the lentiviral pre-integration complex, which does not require nuclear envelope breakdown to access the nucleus. Key application areas include:

• Neuroscience: direct transduction of mature neurons and astrocytes

• Cardiovascular research: transduction of cardiomyocytes and vascular endothelial cells

• Hepatology: transduction of hepatocytes and hepatic stellate cells

• Immunology: transduction of macrophages, dendritic cells, and other antigen-presenting cells

3.2 Genomic Integration and Long-Term Stable Expression

Lentiviral integrase recognizes att sequences at the ends of viral DNA, creates staggered cuts in the host genome, and covalently ligates the viral DNA to the host chromosome. Integration sites are relatively random but tend to favor transcriptionally active regions and intragenic locations. The integrated proviral DNA becomes a permanent part of the host genome, is faithfully replicated with each cell division, and supports stable transgene expression for months to years—or even the lifetime of the organism. Key applications include:

• Stable cell line generation: drug screening, protein production, reporter cell lines

• Long-term gene function studies: chronic disease models, developmental biology

• Cell therapy: CAR-T cell manufacturing, hematopoietic stem cell gene therapy

• Animal models: transgenic animals, disease model development

3.3 Large Packaging Capacity

The effective packaging capacity of lentiviral vectors is 8–10 kb, accommodating the majority of gene therapy and functional research applications. This enables delivery of:

• Full-length cDNA expression constructs

• Polycistronic expression systems

• Complex regulatory elements (tissue-specific promoters, enhancers)

• Dual- or multi-gene co-expression cassettes

• CRISPR–Cas9 system (sgRNA + Cas9)

4. GeneRulor Services

Leveraging years of lentiviral research expertise, GeneRulor offers streamlined and efficient services supporting promoter regulation studies, target gene overexpression, and gene silencing. We provide full-service outsourcing from lentiviral plasmid construction through viral packaging. Our lentiviral packaging services save you the time and effort of constructing lentiviral vectors and packaging virus in-house, delivering ready-to-use lentiviral particles to accelerate your research.

4.1 Service Highlights

• Comprehensive vector portfolio: A broad selection of expression vectors, tag vectors, and reporter genes is available to meet diverse experimental requirements.

• Fast turnaround: Human ORF cDNA clones and Human microRNA clones can be shuttled into lentiviral vectors within 2–3 days, enabling rapid custom lentivirus production.

• Expert customization: Our technical specialists design tailored vector construction strategies based on each client’s specific experimental needs, with full custom service support.

• Consistent performance: Viral titers are determined by absolute quantification using qPCR, and each batch is validated by infection assay in 293T cells to ensure reliable performance.

Fig2. Representative Images of Lentiviral Transduction in Cell Culture

4.2 Frequently Asked Questions (FAQs)

Q1: When should I choose a lentiviral vector?

Lentiviral vectors have a broad host range and can transduce both dividing and non-dividing cells. They are a versatile choice for both in vitro and in vivo studies. Lentivirus is also the ideal vector for generating stable cell lines.

Q2: What is the maximum ORF size that can be cloned into a lentiviral vector?

In general, lentiviral vectors can accommodate inserts up to 8 kb. However, ORF inserts larger than 4 kb substantially reduce packaging efficiency, which in turn lowers viral titer and may impair transgene expression.

Q3: What cell seeding density should be used for lentiviral transduction?

Seed healthy target cells into a 24-well plate at a density of approximately 1×10⁵ cells/mL. The optimal seeding number should account for cell viability, condition, proliferation rate, and division characteristics. As a general guideline, aim for 50–70% cell confluency at the time of transduction.

Q4: What is MOI?

MOI (Multiplicity of Infection) refers to the ratio of viral particles to the number of target cells at the time of transduction. MOI is a dimensionless ratio and has no unit.

Q5: Can lentivirus achieve stable gene expression?

Yes. Lentivirus integrates the transgene into the host genome, ensuring it is passed to daughter cells with each division and is not lost during passage. This enables long-term, stable expression of the transgene.

Q6: What is the typical turnaround time for lentiviral packaging?

If the client provides a pre-constructed lentiviral plasmid, packaging typically takes 2–3 weeks. If upstream vector construction is also required, the total timeline is approximately 4–5 weeks.

Q7: When does transgene expression peak after lentiviral transduction?

Under standard conditions, peak transgene expression is typically reached at 72–96 hours post-transduction. For certain cell types with slow proliferation rates, a longer period may be required to reach peak protein expression.